DBV Technologies Appoints Dr. Philina Lee to Board

DBV Technologies SA – American ( (DBVT) ) has provided an update.

On October 30, 2025, DBV Technologies announced the appointment of Dr. Philina Lee to its Board of Directors, filling the vacancy left by Daniel Soland. Dr. Lee, who brings extensive experience from her previous roles at Blueprint Medicines and Fusion Pharmaceuticals, will also serve on the Compensation Committee. Her appointment, subject to shareholder approval, is expected to enhance DBV’s strategic direction as the company advances its VIASKIN® Peanut program for children with peanut allergies.

The most recent analyst rating on (DBVT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

Spark’s Take on DBVT Stock

According to Spark, TipRanks’ AI Analyst, DBVT is a Neutral.

DBV Technologies SA’s stock score is primarily influenced by strong technical momentum, despite significant financial challenges and unattractive valuation metrics. The stock’s bullish technical indicators suggest potential short-term gains, but long-term stability is uncertain without financial improvement.

To see Spark’s full report on DBVT stock, click here.

More about DBV Technologies SA – American

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is currently investigating its proprietary VIASKIN® patch technology, which uses epicutaneous immunotherapy to address food allergies by introducing microgram amounts of biologically active compounds through the skin. DBV Technologies is headquartered in Châtillon, France, with operations in North America, and its shares are traded on Euronext Paris and the Nasdaq Capital Market.

Average Trading Volume: 91,721

Technical Sentiment Signal: Buy

Current Market Cap: $435.6M

For an in-depth examination of DBVT stock, go to TipRanks’ Overview page.